Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

Regeneron Pharmaceuticals Inc.'s victory against Amgen Inc. over anticompetitive drug bundling reinforces the necessity for ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

Trump has just signed an order that could hike drug prices around the world and he will soon announce pharmaceutical tariffs.

There are many problems with the plan. For instance, it ignores the fact that generic drugs, which make up 90% of ...

President Trump's bombshell executive order aimed at lowering U.S. drug prices is a step toward a worst-case scenario for the ...

U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of ...

The latest price target for Recursion Pharmaceuticals (NASDAQ:RXRX) was reported by Needham on May 6, 2025. The analyst firm set a price target for $8.00 expecting RXRX to rise to within 12 months ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

The United States Patent and Trademark Office (USPTO) issued patent number 12,274,692 to Adial Pharmaceuticals ... a method of treatment for a broad definition of alcohol-related disorders ...

As U.S. and China relations remain tense, concerns are growing over America’s deep reliance on China for critical pharmaceutical ingredients. According to Apollo Asset Management, the ...